Alès (France) – 3 April 2023 – The LFB Group announced today that its subsidiary LFB BIOMANUFACTURING has become a member of the France-BioLead association that supports the production of biopharmaceuticals in France. By joining France-BioLead, LFB BIOMANUFACTURING has chosen to work hand in hand with a host of French players in the sector to put our country on the map of biomanufacturers of the therapeutic innovations of tomorrow.


LFB BIOMANUFACTURING, a heavyweight in the production of recombinant proteins

Through activities ranging from the development of cell lines to the manufacturing of recombinant medicinal products according to GMP (Good Manufacturing Practice) standards, LFB BIOMANUFACTURING has more than 25 years of experience in the field of monoclonal antibodies and recombinant proteins produced by cell culture.


On its industrial site in Alès, in the Gard department of France, LFB BIOMANUFACTURING offers its customers biomanufacturing services as a CDMO (Contract Development and Manufacturing Organisation) with top-notch multifunctional expertise in biomedicinal products. This site has recently expanded to support the growing demand for biopharmaceuticals.

LFB BIOMANUFACTURING also recently rolled out its ESCAPE30 growth strategy that clarifies its goals and defines its long-term priorities. With its ESCAPE30 plan, LFB BIOMANUFACTURING aims for Excellence in CDMO Services for Antibodies and Therapeutic Proteins in Europe by 2030, to thus do its part to build national sovereignty in the field.


Making France a leader in the biomanufacturing of future therapeutic innovations

The France-BioLead association, born from the work of the Strategic Committee of health industrialists and technology players and an important component of France’s Innovation Health 2030 strategy, aims to restore France as the European leader in biomanufacturing.

More information on France BioLead, the French biomanufacturing association: